Exploring Antibodies,
Creating Novel
Therapeutics

Y-Biologics is a company specialized in the research and development of novel antibody drugs, striving to become a global leader in the field of antibody therapeutics by concentrating on the discovery of excellent antibodies and establishment of innovative platform technologies.

Exploring Antibodies,
Creating Novel
Therapeutics

Y-Biologics is a company specialized in the research and development of novel antibody drugs, striving to become a global leader in the field of antibody therapeutics by concentrating on the discovery of excellent antibodies and establishment of innovative platform technologies.

Exploring Antibodies,
Creating Novel
Therapeutics

Y-Biologics is a company specialized in the research and development of novel antibody drugs, striving to become a global leader in the field of antibody therapeutics by concentrating on the discovery of excellent antibodies and establishment of innovative platform technologies.

1 //
scroll down

WHAT WE DOY BIOLOGICS

Y-Biologics is a biopharmaceutical company that specializes in the research & development of novel antibody therapeutics.

  • icon YBL-006

    Korea’s First PD-1 Antibody for Immunotherapy

    YBL-006

    Our anti-PD-1 antibody binds
    to programmed cell death protein-1 (PD-1), an immune checkpoint regulator of T cell activity, to prevent immune evasion and promote the killing of cancer cells.

  • icon YBL-013

    Application of our Proprietary Bispecific T cell Engager Platform, ALiCE

    YBL-013

    Applying our proprietary ALiCE technology, we have developed YBL-013 as a successful pipeline that has been licensed out to our overseas partner, 3DMed.

    Binding both PD-L1-positive cancer cells and T cells, it recruits T cells to the tumor and induces T cell activation
    to eliminate cancer cells.

  • icon ALiCE

    Proprietary Platform Technology Recognized for its Innovativeness and Originality with a Globally Registered Patent

    ALiCE

    Designed in a Y-shaped 2-by-1 format similar to the structure of human antibodies, our ALiCE molecules are capable of binding both a designated cancer target and CD3 on T-cells. Binding to CD3 stimulated T-cell activation, enabling T-cells to directly kill cancer cells bound to the bispecific antibodies, and exhibiting higher efficacy in comparison to conventional immune checkpoint inhibitors.

  • icon Ymax®-ABL

    The Foundation for Y-Biologics’ Pipelines and Open Innovation

    Ymax®-ABL

    Our internally developed and proprietary fully human single-chain variable fragment (scFv) phage display library provides the starting point for each of our novel antibody drug
    R&D projects.

FACT SHEETDATA

Y-Biologics is honing its competitiveness by relentlessly pursuing novel antibody drug R&D to gain antibody-specific technology.

  • icon Company Size
    112

    A continuously growing company with 112 executives and employees

  • icon Technology Transfers
    6

    Antibody R&D Technology Transfers

  • icon Open Innovation
    10

    Joint Research &Development Projects

  • icon Patent Applications
    72

    72 Patent Applications Submitted

  • icon Patent registration
    32

    32 Registered Patents

(As of November 2021)

newsNEWS

Bringing you the latest news from Y-Biologics.

partnershipPARTNER

Partners

Pierre Fabre
3DMed
Pascal Biosciences
Dualogics
LCB
inno.N
ViroCure
WMBIO
Intocell
Giinnovation
IM Biologics